Pre-Clinical Assessment Of RNA-Based Therapeutics For Immuno-Oncology

• Research type

  Research Study

• Full title

  Comprehensive Pre-Clinical Assessment of RNA-Based Therapeutic Strategies Targeting the Immune Response in Solid Tumors for the Advancement of Immuno-Oncology Treatments

• IRAS ID

  349713

• Contact name

  Loic Roux

• Sponsor organisation

  OligoTune

• Duration of Study in the UK

  4 years, 11 months, 31 days

• Research summary

  This study will investigate the pre-clinical potential of RNA-based (ribonucleic acid) therapies to enhance the immune system’s ability to target and destroy solid tumors, including cancers such as lung, breast, and colon cancer. RNA plays a critical role in instructing cells to perform specific functions, such as activating immune responses to fight cancer cells.

  The research will take place in a laboratory setting, utilizing anonymized human blood and tissue samples obtained from healthy donors or patients with diagnosed cancers through academic collaborators, commercial suppliers, or the NHS Blood and Transplant (NHS-BT). The identities of donors will remain confidential, as all samples will be fully anonymized.

  Over the course of five years, the study will involve a series of experiments using in vitro (test tube) model systems to understand how OligoTune's novel RNA therapies activate immune cells. The study will assess the safety and effectiveness of these therapies as potential new cancer treatments. By examining how the immune system interacts with cancer cells, the research aims to inform the development of new therapies that could progress to clinical trials.

  Although this study does not involve direct patient participation, its findings could lead to significant advancements in future cancer treatments.

• REC name

  West Midlands - Solihull Research Ethics Committee

• REC reference

  24/WM/0225

• Date of REC Opinion

  29 Oct 2024

• REC opinion

  Further Information Favourable Opinion